|
Volume 272, Number 29,
Issue of July 18, 1997
pp. 18250-18260
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.
Functional Interactions between the Estrogen Receptor and the
Transcription Activator Sp1 Regulate the Estrogen-dependent
Transcriptional Activity of the Vitellogenin A1 io
Promoter*
(Received for publication, July 16, 1996, and in revised form, April 30, 1997)
Silvia R. Batistuzzo
de Medeiros
§,
Grigorios
Krey
¶,
Abdelmadjid K.
Hihi
and
Walter
Wahli
From the Institut de Biologie animale, Université de
Lausanne, CH-1015 Lausanne, Switzerland
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES
ABSTRACT
Two distinct, TATA box-containing promoters
regulate the transcriptional activity of the Xenopus
vitellogenin A1 gene. These two promoters are of different strength and
are separated by 1.8 kilobase pairs of untranslated sequence. Estrogen
receptor (ER) and its ligand, 17 -estradiol, induce the activity of
both promoters. The estrogen response elements (EREs) are located
proximal to the downstream i promoter while no ERE-like
sequences have been identified in the vicinity of the upstream
io promoter. We show here, that transcriptional activity of
the upstream io promoter is Sp1-dependent.
Moreover, we demonstrate that estrogen inducibility of the
io promoter results from functional interactions between the io bound Sp1 and the ER bound at the proximity of
i. Functional interactions between Sp1 and ER do not
require the presence of a TATA box for transcriptional activation, as
is demonstrated using the acyl-CoA oxidase promoter. The relative
positions that ER and Sp1 occupy with respect to the initiation site
determines whether these two transcription activators can synergize for
transcription initiation.
INTRODUCTION
Transcription is one of the levels at which eukaryotic gene
expression is controlled. Regulation at this level is achieved through
the coordinate and cooperative action of regulatory proteins collectively known as transcription factors. Proteins that regulate RNA
polymerase II-dependent gene expression include the factors that associate with RNA polymerase II and form the transcription initiation complex as well as activators that are not directly involved
with the recruitment of polymerase II to the promoter (reviewed in
Refs. 1 and 2). These latter proteins bind specific DNA elements
located either upstream or downstream of the core promoter and modulate
basal and signal-dependent transcription in a ubiquitous or
specific manner. Nuclear hormone receptors (NHR)1 form the best characterized class of
transcription factors that are activated by extracellular signals
(reviewed in Refs. 3-5). Ligand binding to NHR is correlated with the
transcriptional activation or inhibition of target genes. In some
instances it is a prerequisite for the entry of the receptor into the
nucleus or for DNA binding (reviewed in Ref. 6). Binding of NHR to
target promoters requires the presence of a hormone response element.
These elements, for the most part, consist of two copies of a
hexanucleotide core sequence, which can have direct repeat,
palindromic, or inverted palindrome configurations (reviewed in Ref.
7).
Contrary to the NHRs that control gene expression in developmental
stage-, tissue-, sex specific- and ligand-dependent manner, ubiquitous transcription activators are responsible for the basal expression level of a large number of genes. One such prototypic transcription factor is Sp1, a ubiquitous higher eukaryote protein that
activates transcription through its glutamine-rich transactivation domain (8). As is the case for the nuclear receptors, Sp1 binding to
DNA and subsequent activation of target genes requires the presence of
specific regulatory sequences on the promoters of these genes, known as
GC boxes with the consensus sequence 5 -GGCGGG-3 (9).
The action of transcription activators is thought to be mediated
through direct interactions of the activation domain(s) of these
proteins with components of the basal transcription machinery (10). For
instance, Sp1 has been shown to interact with the TAFII110
component of the TFIID complex (11), while members of the NHR
superfamily, such as the estrogen receptor and COUP-TFI, have been
reported to interact with TAFII30 and TFIIB, respectively (12, 13). Such interactions could be responsible for the recruitment of
additional basal transcription complex factors, the stabilization of
the transcription complex and possibly promoter chromatin
rearrangements, which result in an increased transcriptional activity
from the target promoter.
Promoters of genes regulated by NHRs can contain, in addition to the
hormone response element, binding sites for other transcriptional activators; an additional mechanism of transcriptional fine tuning is,
thus, possible through functional interactions between distinct transcription factors. Indeed, we have shown previously that the estrogen receptor can transcriptionally synergize with the proline-rich transactivation domain of CTF/NF-I on synthetic promoters (14) and that
the peroxisome proliferator-activated receptor (PPAR)/retinoid X
receptor (RXR) heterodimer synergizes with Sp1 for the activation of
the rat acyl-CoA oxidase (ACO) promoter (15).
The genes coding for the egg yolk proteins vitellogenins (vtg) are
among the few known targets of direct estrogen receptor action (16). In
Xenopus laevis four genes, A1, A2, B1 and B2, have been
identified that encode distinct but closely related vtgs. All four
genes are expressed in developmental stage- (adult), tissue-
(hepatocyte), sex- (female), and hormone (estrogen)-dependent manner
(reviewed in Ref. 17). The promoter of the B1 gene is the best
characterized in terms of identification of transcription factor
binding sites and nucleosome positioning (18, 19). Thus, in addition to
the TATA box and estrogen-responsive unit (ERU), there exist several
CTF/NF-I, C/EBP, and HNF-3 binding sites. The vtg A1 gene promoter,
which has not been studied extensively so far, has a unique feature
that consists of the presence of a functional transcription initiation
site, io, located 1.8 kbp upstream of the major
transcription initiation site, i (20). In this work, we have
studied the mechanism of estrogen-dependent stimulation of
the upstream io promoter. We demonstrate that
transcriptional activity from io is mediated by Sp1, which
by functional interactions with the estrogen receptor, bound proximal
to the i transcriptional initiation site, confers estradiol
inducibility to this promoter.
MATERIALS AND METHODS
Construction of Recombinant Plasmids
The reporter plasmids
pA1( 580/+6).CAT, pA1( 1995/+6).CAT, pio.CAT.ERE, and pio.CAT have
been described previously (20). The ERE.ACO.LUC plasmid contains a
single copy of the vtg A2 ERE cloned upstream of position 208 of the
rat acyl CoA-oxidase promoter (21). It was constructed by cloning the
ERE.ACO( 208/+20) BglII-HindIII fragment in the
corresponding sites of the pGL-2 basic vector (Promega). Vectors
pio.TATA.i.CAT and pio.GC.i.CAT were constructed by cloning PCR
amplified fragments containing sequences from 1976 to 1803 and from
1976 to -1848, respectively, of the A1 promoter at position 580
(PstI site) of the pA1( 580/+6).CAT plasmid. The
Xenopus estrogen receptor cloned in the expression plasmid pSG5 (pSG5.xER) has been described previously (22). The expression vector for Sp1 (pPADH.Sp1) has also been described previously (8).
The recombinant plasmid Sp1-24 contains the three GC boxes of the
io promoter, included in the 63-bp
HpaII-HhaI fragment spanning positions 1900 to
1837 of the vtg A1 promoter, in the SmaI site of the pGEM3
vector (Promega). The plasmid Sp1-CAT was constructed by cloning the
62-bp NcoI-FokI fragment, from positions 107 to
168 of the pSV2CAT plasmid (23), which contains the five GC boxes of
the SV40 early promoter, into the SmaI site of pGEM3. Plasmid ESV40 contains a 160-bp fragment, positions 180-340 of the
SV40 enhancer derived from pSV2CAT, cloned into the SmaI
site of pGEM3.
Cell Culture and Transfections
The
Drosophila-derived SL-2 cell line was maintained and
transfected as described previously (15). For the transfection of a
single 3-cm diameter plate, 1 µg of xER expression vector, 2 µg of
Sp1 expression vector, and 3 µg of reporter plasmid were utilized.
For normalization of the transfection efficiency, 0.5 µg of
CMV- -Gal (24) internal control plasmid were also included in each
transfected plate (2.5 × 106 cells). Transfections in
HeLa cells were performed as described previously (22); 0.5 µg of xER
expression vector, 2 µg of reporter plasmid, and 0.5 µg of
CMV- -Gal plasmid were used for each 3-cm diameter plate (2.5 × 105 cells).
Nuclear Extracts
Nuclear extracts from livers of female
X. laevis were prepared as described previously (25).
Nuclear extracts from the Xenopus kidney-derived B3.2 cell
line (a kind gift of Dr. R. Weber, University of Bern, Bern,
Switzerland) and from HeLa cells were prepared as described in Ref.
26.
DNase I Footprinting Assays
For footprint experiments the
probe used was the 226-bp SalI-PstI fragment
derived from the plasmid pA1( 1995/+6).CAT (positions 1995 to 1769
of the vtg A1 promoter). This fragment was end-labeled at the
SalI site with [ -32P]dATP and Klenow enzyme
as described in ref. 27. The binding reaction was performed on ice for
30 min in a buffer containing 41 mM Hepes, pH 7.9, 100 mM KCl, 0.16 mM EDTA, 0.16 mM EGTA,
1.6 mM dithiothreitol, 5 mM MgCl2,
16% glycerol, in a total volume of 20 µl. For each reaction 1.6 ng
of labeled DNA fragment (15,000 cpm) and 1 footprinting unit of
purified Sp1 (Promega) were used. DNase I digestion was performed for 3 min on ice with 50 ng of DNase I (Boehringer Mannheim), diluted in 10 mM Hepes, 25 mM CaCl2, pH 7.9. The
digestion was stopped by the addition of 83 µl of stop buffer
containing 20 mM Tris-HCl, pH 8.0, 250 mM NaCl,
20 mM EDTA, 0.5% SDS, 3 µg of sonicated salmon sperm
DNA, and 10 µg of proteinase K (Boehringer Mannheim). The samples
were incubated at 45 °C for 1 h after which they were extracted
twice with phenol/chloroform and the DNA was precipitated by the
addition of 3 volumes of ethanol. The samples were analyzed on a 8%
sequencing gel along with the G and C + T chemical modification
sequencing reactions of the corresponding DNA fragment.
Electrophoretic Mobility Shift Analysis (EMSA)
For mobility
shift assays, Xenopus liver nuclear extracts (4 µg of
total protein content) were incubated with 1 ng of labeled probe
(Sp1-24) for 30 min on ice in a total volume of 20 µl of binding
buffer containing 26 mM Hepes, pH 7.9, 50 mM
KCl, 5 mM MgCl2, 1.1 mM EDTA, 1 mM dithiothreitol, 20 µM ZnSO4,
20% glycerol, and 4 µg of poly(dI-dC) (Pharmacia Biotech Inc.). For
binding competition experiments, the reactions were carried out as
above with the exception that the nuclear extracts were incubated for 15 min with the competitor DNA before addition of the radiolabeled probe. For antibody-induced supershift, 3 µl of the human monoclonal anti-Sp1 antibody (Santa Cruz Biochemicals) were included in the reaction mixture. The reaction was incubated for 45 min at room temperature. Protein·DNA complexes were separated from the free probe
on a 6% polyacrylamide, 0.5 × TBE (0.09 M Tris
borate, 0.002 M EDTA) gel, and they were visualized by
autoradiography. For EMSA using methylated probes, the reactions were
carried out as above except that either Xenopus liver
nuclear extracts or purified Sp1 (Promega) were incubated 10 min on ice
before adding 1 ng of the corresponding labeled probe for 30 min on
ice.
Metal Replacement Assay
To analyze the importance of
cations for DNA binding of Sp1-like activities, Xenopus
liver nuclear extracts or purified Sp1 were incubated with 50 mM EDTA for 60 min on ice. The mixtures were then dialyzed
twice (1 h each) against 500 ml of the binding buffer used to study
protein-DNA interactions (see above), but which was devoid of
ZnSO4. The dialyzed mixtures were then brought to a
concentration of 0.5 mM metal sulfate salts,
CoSO4, ZnSO4, or NiSO4, and
incubated during 45 min on ice. The mixtures were then tested in EMSA
as described above.
Methylation Interference Assay
Probe Sp1-24 was end-labeled
with [ -32P]dATP at the EcoRI site for the
coding strand and at the BamHI site for the complementary strand. The labeled probes were partially methylated with dimethyl sulfate as described in Ref. 28. The chemically modified probes were
used in EMSA in the conditions described above but scaled-up five
times. Protein·DNA complexes as well as the free probe,
electrophoretically separated and visualized by autoradiography, were
excised from the gel by electroelution for 2 h at 4 °C in TAE
buffer (0.08 M Tris acetate, 0.002 M EDTA).
Following electroelution, an equal volume of a solution containing 50 µg of proteinase K, 20 mM EDTA, and 1% SDS was added to
the samples, which were then incubated for 30 min at 45 °C. The
proteinase K digestion was followed by several phenol/chloroform
extractions before the DNA was precipitated and cleaved with 1 M piperidine for 30 min at 95 °C. The cleaved fragments
were washed several times with 50% methanol before electrophoresis on
a 12% polyacrylamide, 7.5 M urea gel.
In Vitro Transcription
Transcription reactions were
performed in a buffer containing 2.6 mM Tris-HCl, pH 8.0, 20 mM Hepes, pH 7.9, 50 mM KCl, 1 mM MgCl2, 0.5 mM ZnSO4,
0.13 mM ZnCl2, 0.5 mM EDTA, 0.015 mM EGTA, 0.5 mM dithiothreitol, 0.05% Nonidet
P-40, 4 mM spermidine, 5 mM creatine phosphate,
0.6 mM of each ATP, CTP, GTP, and UTP, 40 unites of rRNasin
(Promega), 1 µg of sonicated salmon sperm DNA, 250 ng of test DNA
template (pA1io.CAT.ERE), 100 ng of internal control DNA,
pB1( 41/+8).CAT8+, and 15 µg of B3.2 nuclear extracts. Reactions
were performed as described previously (29), and the transcription
products were detected by primer extension using a CAT gene-specific
primer complementary to the 30 first nucleotides of the CAT gene.
RESULTS
cis-Acting Elements on the io Proximal
Promoter
The organization of the 5 -flanking region of the vtg A1
gene is shown in Fig. 1A. This gene contains
two transcription initiation start sites, determined by two different
TATA box-containing promoters positioned 1.8 kbp apart, termed
i and io for the coding region proximal and
distal initiation sites, respectively. The three imperfect estrogen
response elements (EREs) are located at positions 663, 375, and
333, i.e. between the two promoters, but physically closer
to the i site. Of these three EREs, only the two downstream
elements have been shown to be important for the activation of the
promoter in B3.2 cells (20). Both transcription initiation start sites
have been shown previously to be functional in in vitro
transcription assays using either whole or nuclear HeLa cell extracts.
In addition, both sites are estrogen receptor- and estradiol-inducible
as determined by S1 nuclease analysis using i- and
io-specific primers on RNAs extracted from ER-transfected
and estradiol-treated B3.2 cells or from liver of estradiol-stimulated
Xenopus (20). However, no ERE has been detected up to 2 kbp
upstream of the io promoter. Importantly, in the
transfection experiments, estrogen inducibility of the io
promoter was demonstrated from a template that contains approximately 2 kbp of the A1 promoter (construct pA1( 1995/+6).CAT), i.e.
comprising only 200 bp of sequence upstream of the io
transcription start site (20).
Fig. 1.
A X. laevis nuclear factor binds
to the GC boxes of the vtg A1 promoter. A, schematic
representation of the vtg A1 promoter and sequence of the region
proximal to the upstream io transcription initiation site.
Arrows indicate the transcription initiation sites
i and io (positions +1 and 1805, respectively),
and inverted triangles indicate the positions of the EREs
and squares the positions of the GC boxes. The sequences corresponding
to the GC boxes are underlined. The sequence of the
potential hunchback site (H, underlined) is shown and the locations of the PuF (P) and NF-y (N) sites are
also indicated. B, EMSA demonstrating that a
Xenopus activity from B3.2 cell nuclear extracts binds
specifically to the Sp1-24 probe that contains the GC boxes of the
io promoter. Ca is a specific complex as it is competed with
nonlabeled Sp1-24 probe (lanes 3-5) and with the Sp1-CAT
probe that contains the GC box sequences of the SV40 promoter
(lanes 6-8) but is not competed with the nonrelated ESV40
probe (lanes 9-11). Cx is a nonspecific complex as it is competed with all three nonlabeled probes (lanes 3-11).
FP is the free probe. C, EMSA demonstrating that
a Xenopus activity from hepatocyte nuclear extracts is able
to bind specifically to the Sp1-24-labeled probe resulting in the Ca
complex formation. This is a specific complex as it is competed by the
Sp1-24 and Sp1-CAT nonlabeled probes but not by the unrelated ESV40
sequence. No Cx complex (B) was observed with the hepatocyte
extracts. D, methylation interference on the coding and
noncoding strands of the Sp1-24 probe in the Ca complex from hepatocyte
nuclear extracts. Lanes G and C/T are the
chemical modification sequence reactions for these nucleotides, and
lane F shows the methylation pattern of the noncomplexed
probe (free probe). The methylation protected regions are indicated
with respect to their position on the vtgA1 promoter. An identical
methylation interference pattern on the Sp1-24 probe was obtained with
the B3.2 extracts (not shown).
[View Larger Version of this Image (35K GIF file)]
As no ERE is present upstream of the io promoter, we were
interested in examining the transcription factors that are responsible
for the significant in vitro transcription activity observed
from the upstream io promoter and also to understand the
mechanism by which the estrogen receptor confers inducibility to this
promoter.
Computer-aided analysis of the 200 bp immediately upstream of the
io transcription start site revealed the existence of
several potential cis-acting elements. Of these, the most
evident are three GC-rich motifs situated between positions 1862 and 1848 (numbering of the positions is with respect to the major transcription initiation site i of the vtg A1 gene
promoter). These GC motifs have sequences corresponding to the
consensus Sp1 binding site. In addition, the position of these GC boxes with respect to the initiation site conforms to the criteria previously proposed for Sp1 sites in promoters (30). Of interest also is the
presence of a PuF binding site (31) at positions 1928 to 1917, a
sequence with good homology to the Drosophila hunchback binding site (32) at positions 1896 to 1882 and a CCAAT factor (NF-Y) binding site (33) at positions 1939 to 1930 (see Fig. 1A). In this work, we have analyzed the role of the GC
boxes.
An Activity from Xenopus Nuclear Extracts Recognizes the GC Boxes
of the io Promoter
First, we determined whether the
sequence of the io promoter, containing the three GC-rich
motifs, is recognized by Sp1 or other DNA-binding protein factors
present in Xenopus-derived nuclear extracts. Thus, nuclear
extracts either from the Xenopus B3.2 cell line, or from
Xenopus female hepatocytes were tested by EMSA using as
probe a 64-bp (Sp1-24) fragment containing the GC-rich sequences of the
io promoter. As shown in Fig. 1, nuclear extracts either
from B3.2 cells (Fig. 1B), or from hepatocytes (Fig.
1C), contain an activity that specifically binds to the
64-bp probe, forming the Ca complex in gel retardation assays. The
binding to the probe was efficiently competed by an excess of either
unlabeled Sp1-24 fragment or by an unlabeled fragment (Sp1-CAT)
containing the five GC boxes from the SV40 early promoter, which are
known to bind Sp1 (34). As a control, the ESV40 fragment that contains
no GC boxes was not able to compete for the Ca complex, even at a
250-fold molar excess (Fig. 1, B and C). In
contrast, the nonspecific complex, Cx, which appears only with the B3.2
extracts, was efficiently competed with the ESV40 fragment (Fig.
1B). Faster migrating minor complexes that appear to be
specifically competed by GC box containing DNA sequences (Fig. 1,
B and C) could represent either degradation
products of the major binding activity (Ca) or distinct GC box-binding proteins. Specific binding of the nuclear extract activity to the GC
sequences of the Sp1-24 fragment was demonstrated by methylation interference experiments. As shown in Fig. 1D, methylation
of G residues in the proximal GC box of the io promoter
prevents formation of the Ca complex. Consistently, methylation of the same residues did not influence formation of the nonspecific Cx complex
observed with the B3.2 cell extracts (not shown). Thus, we conclude
that Xenopus nuclear extracts possess an activity that can
specifically recognize the proximal GC box of the io promoter. Based on the G residue methylation interference pattern, which is the same to that observed with purified Sp1 or with Sp1 from
HeLa nuclear cell extracts (see below), we conclude that this activity
is most likely Sp1. Additional evidence in favor of this conclusion is
provided by the observation that the binding activity in
Xenopus hepatocytes did interact with a Sp1 binding site
even when the site is CpG-methylated (Fig. 2,
A and B), a property characteristic of Sp1 (Fig.
2B and Ref. 35). In contrast, as was shown previously Sp1
binding is strongly reduced on binding sites in which some guanines
have been replaced by O6-methylguanines (Fig.
2B and Ref. 36). More importantly, this is also confirmed for the Sp1-like binding activity from Xenopus hepatocyte
nuclear extracts (Fig. 2C). We further characterized the
biochemical properties of the binding activity in Xenopus
hepatocytes by assessing its specific requirement for zinc to bind DNA,
using a metal reconstitution assay. When Sp1 protein is treated
in vitro with EDTA and then challenged with different metal
sulfate salts, it recovers its DNA binding activity when zinc is added,
but not when cobalt and nickel are added (Fig. 2D and Ref.
37). The Sp1-like activity in Xenopus hepatocyte nuclear
extracts presents an identical behavior (Fig. 2D). Thus, in
the several tests presented so far, the analyzed activity from
Xenopus nuclei, which binds to Sp1 sites, has
characteristics identical to those of purified Sp1. Therefore, we
conclude that, most likely, this activity is Xenopus
Sp1.
Fig. 2.
A X. laevis nuclear factor
behaves like purified Sp1 in recognizing methylated DNA probes and in
requiring zinc for DNA binding. A, DNA probes used in EMSA.
The wild-type (wt) sequence corresponds to the GC box region
found in the vtg A1 promoter. The mC probe corresponds to the same
sequence except that CpG methylation was introduced where indicated. In
the mG probe, O6-methylated guanines were
introduced where indicated. B, EMSA demonstrating that the
Xenopus activity binding to the GC boxes of the vtg A1 promoter is specifically competed with the nonlabeled unmethylated probe or with the CpG methylated probe (lanes 4-6), but is
not competed with the O6-guanine-methylated
probe or the unrelated ERE probe (lanes 7 and 8).
The same pattern of binding is observed using labeled CpG methylated
probe (lanes 9-13). Only residual binding is observed when
using the labeled O6-guanine-methylated probe
(lane 14). This is consistent with the observation that the
methylguanine-containing probe is able to specifically compete for
binding to the wild-type sequence only when using large molar excess of
this probe (>300-fold, not shown). C, EMSA demonstrating that purified Sp1 protein is specifically competed with the nonlabeled unmethylated wild-type probe or with the CpG methylated probe (lanes 4-6), but is not competed with the
O6-guanine-methylated probe or the unrelated ERE
probe (lanes 7 and 8). The same pattern of
binding is observed using labeled CpG-methylated probe (lanes 9-13). Only a residual binding is observed when using labeled the
O6-guanine-methylated probe (lane
14). D, EMSA demonstrating that the Xenopus
activity from liver nuclear extracts specifically requires zinc as
a cofactor to bind DNA. EDTA treatment of purified Sp1 results in the
loss of DNA binding activity (lanes 3 and 4). Binding activity is restored when zinc is added (lane 6),
but not when cobalt (lane 5) or nickel (lane 7)
are added. E, EMSA demonstrating that purified Sp1 protein
specifically requires zinc as a cofactor to bind DNA. EDTA treatment of
the extract results in the loss of DNA binding activity (lanes
3 and 4). This activity is restored when zinc is added
(lane 6), but not when cobalt (lane 5) or nickel
(lane 7) are added. Ca is the specific complex.
FP is the free probe.
[View Larger Version of this Image (44K GIF file)]
Purified Sp1 Binds to the GC Boxes of the io
Promoter
Further confirmation of the function of the
io promoter GC boxes as Sp1 binding sites was provided by
the use of purified Sp1 protein in DNase I footprinting and methylation
interference experiments (Fig. 3). In the DNase I
footprint of labeled Sp1-24 probe, Sp1 protected two regions
corresponding to positions 1856 to 1847 and 1884 to 1870 of the
promoter (Fig. 3A). As shown in Fig. 1A, this
region includes the three GC boxes of the io promoter. In
gel retardation assays, binding of Sp1 to the Sp1-24 probe results in
two specific complexes Ca and Cb, for the faster and slower migrating
complexes, respectively (Fig. 3B). Probes partially
methylated and labeled at either strand were used in EMSA with Sp1. The
bound, modified probe from the above Ca and Cb complexes was isolated
and subjected to piperidine cleavage. As shown in Fig. 3B, G
residue methylation in the bound probe reveals Sp1 binding to the
proximal GC box in the case of the Ca complex. Similarly, with the
probe isolated from complex Cb, which apparently results from multiple
Sp1 molecules binding to all three GC boxes of the io
promoter (Fig. 3B), methylation was observed only in the
periphery of these sequences. As expected, activity present in HeLa
cell nuclear extracts interacted with the Sp1-24 probe resulting in an
EMSA complex that could be supershifted with an antibody directed
against human Sp1 (Fig. 3C, left panel). Methylation
interference experiments revealed that the HeLa Sp1 activity interacts
with the proximal GC box of the io promoter (Fig.
3C). It is important to note that the same methylation
interference pattern is observed on this sequence irrespective of the
origin of the binding activity, i.e. nuclear extracts from
Xenopus or HeLa cells, or purified Sp1 (compare Figs.
1D, 3B, and 3C). From the above it is
concluded that Sp1, purified or from HeLa nuclear extracts, is able to
recognize and specifically bind to the GC boxes of the io
promoter. In addition, the activity present in the Ca EMSA complex from
either hepatocyte or B3.2 nuclear cell extracts (Fig. 1, B
and C) is most likely the Xenopus homolog of Sp1,
as already demonstrated above. The human Sp1 monoclonal antibody could
not cross-react with the Xenopus activity either in EMSA or
Western blots (not shown), suggesting that the sequence corresponding
to the antigen epitope is not well conserved between these two species.
This is not surprising considering that the antibody is directed
against an 18-residue-long peptide fragment of the human Sp1
protein.
Fig. 3.
Purified Sp1 binds on the GC boxes of the
io promoter. A, DNase I protection of a DNA
fragment spanning the io promoter initiation site (positions
1995/ 1763, see "Materials and Methods"), in the presence of
purified Sp1. Lanes G, C/T, and F are the same as
described in the legend to Fig. 1C. The positions of the
protected sequences are indicated. B, the EMSA complexes, Ca
and Cb, obtained with purified Sp1 protein and the Sp1-24 probe and
methylation interference of the coding and noncoding strands of these
two complexes. On the EMSA autoradiogram the supershift (SS)
of the two complexes by the anti-Sp1 monoclonal antibody is indicated.
On the methylation interference autoradiograms, lanes G,
C/T, and F are the same as described in the legend Fig. 1C. The regions and G residues (black dots) that
interact with Sp1 as well as the composition of the two complexes are
indicated. Numbering of regions and residues is with respect to the
vtgA1 promoter sequence. C, EMSA and methylation
interference analysis of the endogenous activity from HeLa nuclear cell
extracts (NCE) that interacts with the Sp1-24 probe. In the
EMSA autoradiogram, the major complex, Ca, can be supershifted with the
anti-Sp1 monoclonal antibody. The methylation interference pattern of
the Ca complex is identical to that obtained with purified Sp1 protein
(B) or to that of Xenopus hepatocyte nuclear
extracts.
[View Larger Version of this Image (53K GIF file)]
Sp1 Can Activate Transcription from the io Promoter in
Vitro
Binding of transcription factors to their cognate sites on
a promoter is not sufficient to imply activation of the promoter by
this factor. To ascertain that Sp1 is involved in the transcriptional activation of the io promoter, we employed two different experimental approaches. First, we performed transient transfection experiments in the Drosophila-derived cell line SL-2 with a
reporter plasmid containing the io promoter cloned upstream
of the CAT gene coding sequence (construct pio.CAT, see scheme in Fig. 4A) and a Sp1 expression vector. The choice
of this particular cell line was justified, because, unlike the
mammalian-derived cell lines where Sp1 is ubiquitous, it lacks
endogenous Sp1 activity (8). As shown in Fig. 4A, the
activation of the io promoter, as measured by the level of
CAT activity, can be amplified by at least 20-fold when the reporter
plasmid is cotransfected with the Sp1 expression vector. In contrast,
the basal activity of the vtg B1 gene proximal promoter (promoter
positions 41 to 8), that does not contain Sp1 sites (38), does not
exhibit a similar Sp1-dependent activation (not shown, see
below). The above strongly suggest that activation of the io
promoter is Sp1-dependent.
Fig. 4.
Sp1 activates transcription from the
io promoter in SL-2 cells and in vitro.
A, Drosophila SL-2 cells were transfected with
the pio.CAT reporter plasmid, schematically represented on the
top of the figure (squares represent the GC
boxes, the oval represents the TATA box, and the
arrow represents the transcription initiation site), in the
absence (pPADH) or presence of the Sp1 expression plasmid
(Sp1) as indicated. The average, with standard deviation, of
three independent experiments is shown. B, in vitro transcription assay from the plasmid pio.CAT (io, 115 nucleotides) and the control vtg B1 promoter (ic, 89 nucleotide), in the presence of B3.2 nuclear extracts and increasing
amounts of purified Sp1 (lanes 1-4). Transcription from
io is inhibited in the presence of a 375 molar excess of the
specific competitor Sp1-CAT double-stranded oligonucleotide (lane
5), but it is not affected by the presence of the nonspecific ERE
and Ad1 DNA fragments (lanes 6 and 7,
respectively). C, the endogenous Xenopus Sp1-like
activity stimulates transcription from the io promoter in
the absence of purified Sp1 (lane 1). B3.2 nuclear
extract-dependent transcription from the io
promoter can be inhibited with increasing amounts of the Sp1-CAT DNA
fragment (0.6, 0.12, 0.24, 0.48, 0.96, 1.9, 3.8, and 7.6 pM, lanes 2-9, respectively). M is
the molecular marker lane; io and ic are the same as in B. D, purified Sp1 protein (10 or 30 ng, lanes 3 and
4, respectively) restores transcription from the
io promoter in B3.2 nuclear extracts that have been depleted
of the GC box binding activity by the addition of 14 pM of
the Sp1-CAT DNA fragment (lane 2). Lane 1 represents transcription from the io promoter due to the
endogenous Sp1-like activity of the B3.2 nuclear extracts.
[View Larger Version of this Image (26K GIF file)]
The second approach consisted of an in vitro transcription
assay in which the reporter plasmids that were used in the transfection assay, i.e. pio.CAT and the vtg B1 control plasmid (promoter
positions 41 to 8), were used as templates of transcription.
Transcription from the above templates was carried in B3.2 cell nuclear
extracts in the presence or absence of purified Sp1 protein. As can be seen in Fig. 4B, increasing amounts of Sp1 resulted in
strong induction of transcript synthesis from the io
promoter but not from the control (ic), the truncated vtg B1 promoter. That the Sp1 effect was indeed mediated through the GC boxes of the
io promoter was established by competition experiments using
specific and nonspecific oligonucleotide competitors. Indeed, inhibition of transcription was observed when a 375 molar excess of the
60-bp fragment containg the 5 GC boxes of the SV40 promoter was used,
while an equal concentration of a double-stranded ERE oligonucleotide,
or a sequence containing the replication origin of adenovirus 2, did
not lower the transcription levels of the io promoter. The
modest increase in transcriptional activity observed in the presence of
the nonspecific competitors (compare lane 3 with lanes
6 and 7 in Fig. 4B) is likely to be the
result of a titrating out of DNA-binding proteins that interact in a nonspecific manner with the io promoter. Release of these nonspecific interactions would then allow better binding of Sp1 to the
promoter and, thus, increase transcription. This in vitro assay was also used as an indirect demonstration of the involvement of
the B3.2 endogenous Sp1 activity, which was detected with the EMSA (see
Fig. 1B), in transcriptional activation. Transcription reactions were performed in the absence of purified Sp1 and with increasing amounts of the 60-bp SV40 promoter fragment able to titrate
out the endogenous Sp1. As shown in Fig. 4C, io transcript inhibition was proportional to the amount of competitor present in the assay, which however, did not affect the control promoter. Furthermore, transcription from the io promoter in
extracts depleted from the GC box binding activity could be restored by
the addition of purified Sp1 protein (Fig. 4D). The above
results demonstrate that both in transient transfection experiments as
well as in in vitro transcription assays, Sp1 is necessary
and sufficient to stimulate transcription from the io promoter.
ER and Sp1 Synergize for the Activation of the io
Promoter
S1 nuclease analysis has been previously used to
demonstrate that the activity of the io promoter is
ER-inducible when in the entire vtg A1 gene promoter context (20). This
result suggests that ER bound to the ERU may be involved in the
regulation of the upstream io promoter. Since the ERU is
relatively far downstream of io, the involvement of ER in
the activation of the io promoter could be explained if
functional interactions of ER with transcription factors,
i.e. Sp1, bound close to the io initiation site
could occur. Thus, we explored this possibility. Using the
Drosophila-derived SL-2 cell line, we have recently
demonstrated that the nuclear hormone receptors PPAR and RXR can
functionally interact with Sp1 for the transcriptional regulation of
the ACO gene promoter (15). Therefore, we have used the same approach
to investigate potential interactions of ER with Sp1 bound at
io.
We utilized the pio.CAT.ERE reporter in which the io
promoter is separated from the ERE by the CAT gene coding sequences (1.6 kbp) and thus, in that aspect, corresponds to the topological arrangement of the ER and Sp1 binding sites on the native A1 promoter (see scheme in Fig. 5A). The pio.CAT.ERE
reporter plasmid has only a weak basal activity, when transfected in
SL-2 cells in the absence of both ER and Sp1 expression vectors.
Similarly, expression of ER alone has negligible effect on CAT
transcription (Fig. 5A). In contrast, expression of Sp1
results in significant induction of CAT activity that is, nevertheless,
hormone-independent. When both ER and Sp1 are expressed, a strong
synergistic effect is observed between them, in the presence of
17 -estradiol, which results in CAT activity 4-fold higher than that
of Sp1 transfected alone (Fig. 5A). Thus, the ER function as
an activator depends on the presence of bound Sp1 to the io
promoter, implying that functional interactions between the two
proteins are essential for high transcriptional activity from the vtg
A1 io promoter.
Fig. 5.
ER and Sp1 synergize for the transcriptional
activation of the io and ERE.ACO promoters. A,
SL-2 cells were transfected with the pio.CAT.ERE reporter plasmid and
expression vectors for ER and Sp1 in the presence (E2) or
absence (N.I.) of 17 -estradiol as indicated. A schematic
representation of the reporter plasmid is also shown;
squares represent the GC boxes, inverted
triangles the EREs, the oval the TATA box, and the
arrow the transcription initiation site. B, SL-2
cells were transfected with the ERE.ACO.LUC reporter plasmid and the ER
and Sp1 expression plasmids as in A. Luciferase reporter
activity values are with respect to the activity resulting from the
transfection of the Sp1 expression plasmid alone. The inset
shows a magnified view of the ER alone-mediated transcriptional
activity. The schematic representation of the reporter is also shown;
symbols are the same as in A. The average, with standard
deviation, of three independent experiments is shown.
[View Larger Version of this Image (14K GIF file)]
Functional interactions between ER and Sp1 were also demonstrated on
another reporter construct (ERE.ACO.LUC, see scheme Fig. 5B)
where an ERE is inserted upstream of the first four Sp1 sites in the
proximal region (position 208) of the TATA-less ACO promoter (15, 21, see scheme in Fig. 5B). As in the above case, a similar estradiol-dependent, superactivation of transcription is
observed from this promoter when both ER and Sp1 are present, reaching a level 6-fold higher than that obtained with Sp1 alone (Fig. 5B). However, in contrast to the pio.CAT.ERE reporter, a
weak ER and estradiol-dependent stimulation of the ERE.ACO
promoter is obtained in the absence of Sp1 (Fig. 5B, inset).
The obvious difference between these two reporter constructs is the
position of the ERE with respect to the transcription initiation site. In the case of ERE.ACO.LUC the ERE is situated 208 bp upstream of the
transcription initiation site, while it is situated 1.7 kbp downstream
of io (4.7 kbp upstream) in the case of pio.CAT.ERE. Thus,
it appears likely that, depending on the distance separating the ERE
from the transcription initiation site, ER/Sp1 synergism confers
estrogen inducibility (see pio.CAT.ERE) or strongly amplifies a weak ER
response (see ERE.ACO.LUC).
Sp1, Bound to the io Promoter, Is Not Involved in the
Transcriptional Activity of the Downstream i
Promoter
Although the above results clearly demonstrate that ER
and Sp1 synergize for the activation of the io promoter and of the hybrid ERE.ACO.LUC promoter, they do not address the question of
whether this synergism affects the i promoter activity as
well (see Fig. 1A for location of the i
promoter).
To test this possibility, different A1 promoter-driven reporter
plasmids were constructed in which the io promoter was
either deleted or the intervening sequences between the ERU and the
io promoter were eliminated (Fig.
6A). These constructs were used for transient
transfections in HeLa cells in the presence or absence of estradiol and
the ER expression vector. The results of these transfection experiments
are summarized in Fig. 6B. The pA1( 1995/+6).CAT construct
(I in Fig. 6A), that contains both the
i and io promoters as well as the intervening sequences between the two sites, is active and inducible by ER in the
presence of estradiol. Similarly, the pio.TATA.i.CAT construct (II in Fig. 6A), in which the intervening
sequences between the io promoter and the ERU of the
i promoter have been deleted, is also inducible by estradiol
and ER and the induction factor (5-fold) as well as the absolute CAT
activity, are equivalent to those observed with the pA1( 1995/+6).CAT
reporter plasmid (Fig. 6B). Thus, positioning of the
io promoter proximal to the ERU does not influence the
transcriptional activity of the i promoter. Construct
pio.GC.i.CAT (construct III in Fig. 6A), that
lacks the sequences between position -580 and the Sp1 binding sites of
the i promoter, was used to establish whether the presence
of a TATA box between the ERU and the Sp1 sites is restrictive to
interactions between the two activators. In addition, the Sp1 sites are
closer to the ERU in this construct. Again, with this construct,
ER/E2-dependent transcriptional activity and
induction were similar to the pA1( 1995/+6).CAT and pio.TATA.i.CAT constructs. Finally, the ER/E2-dependent
induction profile from construct pA1( 580/+6).CAT (construct
IV in Fig. 6A), that lacks the sequences upstream of
position 580, was similar to that observed with constructs
pA1( 1995/+6).CAT, pio.TATA.i.CAT, and pio.GC.i.CAT (Fig.
6B). These similar activation profiles indicate the absence of synergistic interactions between ER and Sp1 for the activation of
the i promoter, in contrast to what we have observed above
for the io promoter. This does not seem to be a per se sequence context-mediated event but rather reflects the
requirements for proper topological arrangement of trans
factors on the promoter. Thus, it appears that binding of Sp1 upstream
to the ER, that is at a distance from the i promoter, is not
a favorable configuration for functional interactions between the two
transcription activators for i promoter stimulation.
Fig. 6.
Sp1 bound to the io promoter does
not contribute to the ER-mediated activation of the i
promoter. A, schematic representation of the vtg A1 promoter
deletion constructs (I-IV, see "Materials and
Methods"). Arrows represent transcription initiation
sites, ovals the TATA boxes, squares the GC
boxes, and inverted triangles the EREs. B, the
vtg A1 constructs in A (roman numerals) were transfected in HeLa cells in the presence or absence of ER expression vector and 17 -estradiol (E2) as indicated. -Fold
induction values correspond to CAT activity due to
E2-induced ER over the activity due to noninduced ER, for
each reporter construct individually. The average, with standard
deviation, of three independent experiments is shown. pSG5
stands for the empty (no ER coding sequences) expression vector.
[View Larger Version of this Image (15K GIF file)]
DISCUSSION
In this study we have used in vitro assays as
well as transient transfection experiments to identify the
cis- and trans-acting elements that control
transcriptional activity from the io promoter, the upstream
promoter of the Xenopus vtg A1 gene. The in vitro
transcription assay, coupled to EMSA and methylation interference
assays, demonstrated that the GC-rich sequences, in the proximity of
the TATA box of this promoter, serve as binding sites for either
purified Sp1 protein or for an endogenous Xenopus activity
with similar properties. Presently, Sp1 or other members of the Sp
family from Xenopus have not been characterized and therefore, we cannot speculate on the interspecies structural differences of these transcriptional activators. However, several lines
of evidence suggest that the activity present in the Xenopus derived nuclear extracts, able to recognize the GC boxes of the io promoter, is the homolog of Sp1. Previous studies (39) have shown that the G residues of the sequence 5 -GGGCG-3 ,
i.e. four on the guanine-rich strand and one on the
cytosine-rich strand, are the major sites of Sp1-GC box interactions.
Our methylation interference experiments establish that the
Xenopus activity interacts precisely with these residues of
the GC boxes of the io promoter. Furthermore, like Sp1 this
Xenopus activity binds DNA even when the binding site is CpG
methylated and, also like Sp1, it has a reduced binding when some
guanines in the binding site are replaced by
O6-methylguanines. Furthermore, it specifically requires zinc as a metal cofactor to efficiently bind its target DNA
sequence, just like purified Sp1 (37). Consistent with these findings,
induction of transcriptional activity from the io promoter
is dependent on the presence of purified Sp1 protein or on the
endogenous Xenopus activity in the in vitro
assay. Importantly, addition of purified Sp1 protein could restore
transcriptional activity, specific to the io promoter, in
nuclear extracts depleted from all GC box-binding proteins. A further
argument for the identity of the Xenopus activity as Sp1 is
that Sp3, the protein most closely related to Sp1 in terms of size,
structure, expression pattern, and DNA sequence recognition (40), is a transcriptional repressor (41, 42). Our in vitro
transcription assay results clearly demonstrate that the
Xenopus activity has a stimulatory effect on transcription.
The above conclusions are further supported by the results of transient
transfections in a Drosophila-derived cell line devoid of
endogenous Sp1-like activity. Indeed, we demonstrated that
cotransfection of the Sp1 expression vector, along with a reporter
plasmid under the control of the io promoter, was necessary
and sufficient for basal transcriptional activity from this
promoter.
Transient transfections in the SL-2 cell line were further used to
explore the mechanism responsible for the previously observed ER-dependent transcriptional inducibility of the
io promoter (20). Herein, we have demonstrated that this
effect is mediated through functional synergism between ER and Sp1.
Functional interactions between ER and Sp1 were also demonstrated on a
TATA-less promoter consisting of the proximal ACO promoter, that
contains four Sp1 binding sites, artificially fused to an ERE. Thus,
such interactions are not restricted to promoters containing a TATA
box. However, it is important to note that the topological arrangement
of the cis elements appears to be an important parameter in
determining the ability of a trans factor to act as an
activator as well as in allowing functional interactions between
different activators. Thus, on the promoter constructs studied here,
the ER by itself cannot act as a transcriptional enhancer when the ERE
is located at a distance from the transcription initiation site.
However, binding of Sp1 to the proximity of the transcription
initiation site converts the distally bound ER to a strong activator of
transcription. In contrast, as the experiments with the ERE.ACO
promoter demonstrate, Sp1 binding to the proximal promoter or the
presence of a TATA box is not essential for ER-dependent
activation when the ER is bound close to the transcription initiation
site, but Sp1 dramatically amplifies the hormonal stimulation.
The function of Sp1 as an enhancer is still a matter of debate as
conflicting results have been reported in the literature (43, 44).
However, even in the case where the ability of Sp1 to act as a distal
enhancer has been demonstrated, this effect is marginal and is
dependent on high Sp1 concentrations. Our transient transfection
experiments with reporter constructs in which the intervening sequence
between the two promoters of the vtg A1 gene were deleted suggest that,
at physiological concentrations, Sp1 must bind proximal to the
transcription initiation site to enhance transcription. In addition,
binding of Sp1 close to the initiation site appears to be a requirement
for positive interactions of this activator with the ER. This is also
supported from our previous analysis of the ACO promoter where we had
shown that the most distal (upstream) Sp1 binding site of this promoter
does not contribute to the synergism between the PPAR/RXR heterodimer
and Sp1 (15).
The nature of the interactions between ER and Sp1 that lead to
functional synergism of these two transcription factors is not yet
elucidated. It has been reported that Sp1 stabilizes weak interactions
of ER with an ERE half-site provided that this element is adjacent to a
Sp1 site, as is the case in a number of naturally occurring promoters
(45, 46), in contrast to the situation studied herein. However, direct
contacts between the two proteins have not been observed even when they
are bound to adjacent sites. Besides the reciprocal stabilization of
the DNA binding abilities of the two proteins to their corresponding
cis elements, at least three additional mechanisms could
account for their synergistic effect on transcription. First, the
documented interactions of ER and Sp1 with TAFII30 and
TAFII110, respectively, may be responsible for the
recruitment and stabilization of the RNA polymerase II holoenzyme on
promoters that contain ER and Sp1 binding sites. Second, it is possible
that ER and Sp1 interact with a common co-activator. Recruitment of
this co-activator on the promoter could then result in increased
affinity of the transcription initiation complex for this promoter.
Finally, the established interaction of Sp1 with histone H3 (47) may
contribute to chromatin reorganization in the vicinity of the
io promoter, thus enhancing transcription from this
site.
FOOTNOTES
*
This work was supported by the Swiss National Science
Foundation and the Etat de Vaud.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
These authors contributed equally to this work.
§
Supported by a fellowship from the CNPq, Brazilian Agency. Present
address: Dept. de Biologia Cellular e Genetica-CB-UFRN, Natal, RN CEP
59015-310, Brazil.
¶
Supported by Ciba-Geigy.
To whom correspondence should be addressed: Institut de
Biologie animale, Bâtiment de Biologie, Université de
Lausanne, CH-1015 Lausanne, Switzerland. Tel.: 41-21-692-4110; Fax:
41-21-692-4115; E-mail: walter.wahli{at}iba.unil.ch.
1
The abbreviations used are: NHR(s), nuclear
hormone receptor(s); vtg, vitellogenin; ER, estrogen receptor; ERE,
estrogen response element; ERU, estrogen response unit; bp, base
pair(s); kbp, kilobase pair(s); nt, nucleotide; EMSA, electrophoretic
mobility shift analysis; ACO, acyl-CoA oxidase; PPAR, peroxisome
proliferator activated receptor; RXR, retinoic X receptor; CAT,
chloramphenicol acetyltransferase; E2,
17 -estradiol.
ACKNOWLEDGEMENTS
We thank A. Alevizopoulos and N. Mermod for
critical reading of this manuscript and for helpful discussions.
REFERENCES
-
Tjian, R., and Maniatis, T.
(1994)
Cell
77,
5-8
[CrossRef][Medline]
[Order article via Infotrieve]
-
Zawel, L., and Reinberg, D.
(1993)
Prog. Nucleic Acid Res. Mol. Biol.
44,
67-108
[Medline]
[Order article via Infotrieve]
-
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., and Evans, R. M.
(1995)
Cell
83,
835-839
[CrossRef][Medline]
[Order article via Infotrieve]
-
Evans, R. M.
(1988)
Science
240,
889-895
[Abstract/Free Full Text]
-
Wahli, W., and Martinez, E.
(1991)
FASEB J.
5,
2243-2249
[Abstract]
-
Beato, M., Herrlich, P., and Schütz, G.
(1995)
Cell
83,
851-857
[CrossRef][Medline]
[Order article via Infotrieve]
-
Glass, C. K.
(1994)
Endocr. Rev.
15,
391-407
[Abstract/Free Full Text]
-
Courey, A. J., and Tjian, R.
(1988)
Cell
55,
887-898
[CrossRef][Medline]
[Order article via Infotrieve]
-
Dynan, W. S., and Tjian, R.
(1985)
Nature
316,
774-778
[CrossRef][Medline]
[Order article via Infotrieve]
-
Choy, B., and Green, M. R.
(1993)
Nature
366,
531-536
[CrossRef][Medline]
[Order article via Infotrieve]
-
Hoey, T., Weinzierl, R. O. J., Gill, G., Chen, J. L., Dynlacht, B. D., and Tjian, R.
(1993)
Cell
72,
247-260
[CrossRef][Medline]
[Order article via Infotrieve]
-
Jacq, X., Brou, C., Lutz, Y., Davidson, I., Chambon, P., and Tora, L.
(1994)
Cell
79,
107-117
[CrossRef][Medline]
[Order article via Infotrieve]
-
Ing, N. H., Beekman, J. M., Tsai, S. Y., Tsai, M.-J., and O'Malley, B. W.
(1992)
J. Biol. Chem.
267,
17617-17623
[Abstract/Free Full Text]
-
Martinez, E., Dusserre, Y., Wahli, W., and Mermod, N.
(1991)
Mol. Cell. Biol.
11,
2937-2945
[Abstract/Free Full Text]
-
Krey, G., Mahfoudi, A., and Wahli, W.
(1995)
Mol. Endocrinol.
9,
219-231
[Abstract/Free Full Text]
-
Wahli, W., Dawid, I. B., Ryffel, G. U., and Weber, R.
(1981)
Science
212,
298-304
[Abstract/Free Full Text]
-
Wahli, W.
(1988)
Trends Genet.
4,
227-232
[CrossRef][Medline]
[Order article via Infotrieve]
-
Cardinaux, J.-R., Chapel, S., and Wahli, W.
(1994)
J. Biol. Chem.
269,
32947-32956
[Abstract/Free Full Text]
-
Schild, C., Claret, F. X., Wahli, W., and Wolffe, A.
(1993)
EMBO J.
12,
423-433
[Medline]
[Order article via Infotrieve]
-
Tremea, F., Batistuzzo de Medeiros, S. R., ten Heggeler-Bordier, B., Germond, J. E., Seiler-Tuyns, A., and Wahli, W.
(1989)
Mol. Endocrinol.
3,
1596-1609
[Abstract/Free Full Text]
-
Osumi, T., Ishii, N., Miyazama, S., and Hashimoto, T.
(1987)
J. Biol. Chem.
262,
8138-8143
[Abstract/Free Full Text]
-
Claret, F.-X., Chapel, S., Garcés, J., Tsai-Pflugfelder, M., Bertholet, C., Shapiro, D. J., Wittek, R., and Wahli, W.
(1994)
J. Biol. Chem.
269,
14047-14055
[Abstract/Free Full Text]
-
Gorman, C. M., Moffat, L. F., and Howard, B. H.
(1982)
Mol. Cell. Biol.
2,
1044-1051
[Abstract/Free Full Text]
-
MacGregor, G. R., and Caskey, C. T.
(1989)
Nucleic Acids Res.
17,
2365
[Free Full Text]
-
Corthésy, B., Hipskind, R., Theulaz, I., and Wahli, W.
(1988)
Science
239,
1137-1139
[Abstract/Free Full Text]
-
Shapiro, D. J., Sharp, P. A., Wahli, W., and Keller, M. J.
(1988)
DNA (N. Y.)
7,
47-55
[Medline]
[Order article via Infotrieve]
-
Maniatis, T., Fritsch, E. F., and Sambrook, J.
(1982)
Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
-
Maxam, A., and Gilbert, W.
(1980)
Methods Enzymol.
65,
499-560
[Medline]
[Order article via Infotrieve]
-
Corthésy, B., and Wahli, W.
(1989)
DNA Protein Eng. Tech.
2,
68-71
-
Kadonaga, J. T., Jones, K. A., and Tjian, R.
(1986)
Trends Biochem. Sci.
11,
20-23
-
Postel, E. H., Mango, S. E., and Flint, S. J.
(1989)
Mol. Cell. Biol.
9,
5123-5133
[Abstract/Free Full Text]
-
Treisman, J., and Desplan, C.
(1989)
Nature
341,
335-337
[CrossRef][Medline]
[Order article via Infotrieve]
-
Faber, M., and Sealy, L.
(1990)
J. Biol. Chem.
265,
22243-22254
[Abstract/Free Full Text]
-
Kadonaga, J. T., and Tjian, R.
(1986)
Proc. Natl. Acad. Sci. U. S. A.
83,
5889-5893
[Abstract/Free Full Text]
-
Höller, M., Westin, G., Jiricny, J., and Schaffner, W.
(1988)
Genes Dev.
2,
1127-1135
[Abstract/Free Full Text]
-
Bonfanti, M., Broggini, M., Prontera, C., and D'Incalci, M.
(1991)
Nucleic Acids Res.
19,
5739-5742
[Abstract/Free Full Text]
-
Kadonaga, J. T., Carner, K. R., Masiarz, F. R., and Tjian, R.
(1987)
Cell
51,
1079-1090
[CrossRef][Medline]
[Order article via Infotrieve]
-
Corthésy, B., Cardinaux, J. R., Claret, F. X., and Wahli, W.
(1989)
Mol. Cell. Biol.
9,
5548-5562
[Abstract/Free Full Text]
-
Kuwahara, J., Yonzawa, A., Futamura, M., and Sugiura, Y.
(1993)
Biochemistry
32,
5994-6001
[CrossRef][Medline]
[Order article via Infotrieve]
-
Kingsley, C., and Winoto, A.
(1992)
Mol. Cell. Biol.
12,
4251-4261
[Abstract/Free Full Text]
-
Dennig, J., Hagen, G., Beato, M., and Suske, G.
(1995)
J. Biol. Chem.
270,
12737-12744
[Abstract/Free Full Text]
-
De Luca, P., Majello, B., and Lania, L.
(1996)
J. Biol. Chem.
271,
8533-8536
[Abstract/Free Full Text]
-
Courey, A. J., Holtzman, D. A., Jackson, S. P., and Tjian, R.
(1989)
Cell
59,
827-836
[CrossRef][Medline]
[Order article via Infotrieve]
-
Seipel, K., Georgiev, O., and Schaffner, W.
(1992)
EMBO J.
11,
4961-4968
[Medline]
[Order article via Infotrieve]
-
Wu-Peng, S. X., Pugliese, T. E., Dickerman, H. W., and Pentecost, B. T.
(1992)
Mol. Endocrinol.
6,
231-240
[Abstract/Free Full Text]
-
Krishnan, V., Wang, X., and Safe, S.
(1994)
J. Biol. Chem.
269,
15912-15917
[Abstract/Free Full Text]
-
Alevizopoulos, A., Dusserre, Y., Tsai-Pflugfelder, M., von der Weid, T., Wahli, W., and Mermod, N.
(1995)
Genes Dev.
9,
3051-3066
[Abstract/Free Full Text]
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Safe and K. Kim
Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways
J. Mol. Endocrinol.,
November 1, 2008;
41(5):
263 - 275.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Maynadier, J.-M. Ramirez, A.-M. Cathiard, N. Platet, D. Gras, M. Gleizes, M. S. Sheikh, P. Nirde, and M. Garcia
Unliganded estrogen receptor {alpha} inhibits breast cancer cell growth through interaction with a cyclin-dependent kinase inhibitor (p21WAF1)
FASEB J,
March 1, 2008;
22(3):
671 - 681.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Zhang, X. Xie, X. Zhu, J. Zhu, C. Hao, Q. Lu, L. Ding, Y. Liu, L. Zhou, Y. Liu, et al.
Stimulatory Cross-talk between NFAT3 and Estrogen Receptor in Breast Cancer Cells
J. Biol. Chem.,
December 30, 2005;
280(52):
43188 - 43197.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Bardin, F. Moll, R. Margueron, C. Delfour, M. L. Chu, T. Maudelonde, V. Cavailles, and P. Pujol
Transcriptional and Posttranscriptional Regulation of Fibulin-1 by Estrogens Leads to Differential Induction of Messenger Ribonucleic Acid Variants in Ovarian and Breast Cancer Cells
Endocrinology,
February 1, 2005;
146(2):
760 - 768.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Fujita, M. Kajita, P. Taysavang, and P. A. Wade
Hormonal Regulation of Metastasis-Associated Protein 3 Transcription in Breast Cancer Cells
Mol. Endocrinol.,
December 1, 2004;
18(12):
2937 - 2949.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. L. Zheng, W. Zheng, B.-l. Chang, X.-O. Shu, Q. Cai, H. Yu, Q. Dai, J. Xu, and Y.-T. Gao
Joint Effect of Estrogen Receptor {beta} Sequence Variants and Endogenous Estrogen Exposure on Breast Cancer Risk in Chinese Women
Cancer Res.,
November 15, 2003;
63(22):
7624 - 7629.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Nilsson, S. Makela, E. Treuter, M. Tujague, J. Thomsen, G. Andersson, E. Enmark, K. Pettersson, M. Warner, and J.-A. Gustafsson
Mechanisms of Estrogen Action
Physiol Rev,
October 1, 2001;
81(4):
1535 - 1565.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Klinge
Estrogen receptor interaction with estrogen response elements
Nucleic Acids Res.,
July 15, 2001;
29(14):
2905 - 2919.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Lu, G. Jenster, and D. E. Epner
Androgen Induction of Cyclin-Dependent Kinase Inhibitor p21 Gene: Role of Androgen Receptor and Transcription Factor Sp1 Complex
Mol. Endocrinol.,
May 1, 2000;
14(5):
753 - 760.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
P. S. Jones, E. Parrott, and I. N. H. White
Activation of Transcription by Estrogen Receptor alpha and beta Is Cell Type- and Promoter-dependent
J. Biol. Chem.,
November 5, 1999;
274(45):
32008 - 32014.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Griffin, G. Flouriot, V. Sonntag-Buck, and F. Gannon
Two Functionally Different Protein Isoforms Are Produced from the Chicken Estrogen Receptor-{alpha} Gene
Mol. Endocrinol.,
September 1, 1999;
13(9):
1571 - 1587.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
M. S. Ricci, D. G. Toscano, C. J. Mattingly, and W. A. Toscano Jr.
Estrogen Receptor Reduces CYP1A1 Induction in Cultured Human Endometrial Cells
J. Biol. Chem.,
February 5, 1999;
274(6):
3430 - 3438.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. A. Stafford and R. H. Morse
Mutations in the AF-2/Hormone-binding Domain of the Chimeric Activator GAL4·Estrogen Receptor·VP16 Inhibit Hormone-dependent Transcriptional Activation and Chromatin Remodeling in Yeast
J. Biol. Chem.,
December 18, 1998;
273(51):
34240 - 34246.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. J. Scheidegger, B. Cenni, D. Picard, and P. Delafontaine
Estradiol Decreases IGF-1 and IGF-1 Receptor Expression in Rat Aortic Smooth Muscle Cells. MECHANISMS FOR ITS ATHEROPROTECTIVE EFFECTS
J. Biol. Chem.,
December 1, 2000;
275(49):
38921 - 38928.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1997 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|